Trade Alnylam Pharmaceuticals, Inc. - ALNY CFD
Add to favourite- Summary
- Historical Data
| Spread | 1.90 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 237.7 |
| Open | 234.78 |
| 1-Year Change | 25.31% |
| Day's Range | 234.78 - 246.72 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 244.90 | 9.90 | 4.21% | 235.00 | 246.94 | 234.78 |
| Dec 19, 2024 | 237.70 | 1.61 | 0.68% | 236.09 | 241.44 | 232.80 |
| Dec 18, 2024 | 236.36 | -6.17 | -2.54% | 242.53 | 246.45 | 236.36 |
| Dec 17, 2024 | 245.34 | 2.93 | 1.21% | 242.41 | 249.32 | 240.46 |
| Dec 16, 2024 | 243.56 | -0.50 | -0.20% | 244.06 | 247.59 | 242.03 |
| Dec 13, 2024 | 244.35 | 0.22 | 0.09% | 244.13 | 249.33 | 241.42 |
| Dec 12, 2024 | 243.97 | -10.98 | -4.31% | 254.95 | 254.95 | 243.97 |
| Dec 11, 2024 | 252.79 | 1.15 | 0.46% | 251.64 | 255.05 | 250.01 |
| Dec 10, 2024 | 252.76 | -2.81 | -1.10% | 255.57 | 256.76 | 248.98 |
| Dec 9, 2024 | 254.60 | -0.37 | -0.15% | 254.97 | 257.66 | 251.91 |
| Dec 6, 2024 | 254.57 | 3.92 | 1.56% | 250.65 | 256.80 | 249.76 |
| Dec 5, 2024 | 250.64 | 2.04 | 0.82% | 248.60 | 255.03 | 248.60 |
| Dec 4, 2024 | 253.84 | 6.39 | 2.58% | 247.45 | 256.25 | 247.45 |
| Dec 3, 2024 | 250.74 | 1.13 | 0.45% | 249.61 | 252.90 | 245.89 |
| Dec 2, 2024 | 251.85 | -0.06 | -0.02% | 251.91 | 255.08 | 250.43 |
| Nov 29, 2024 | 252.20 | 2.25 | 0.90% | 249.95 | 253.33 | 248.96 |
| Nov 27, 2024 | 253.29 | 3.33 | 1.33% | 249.96 | 255.38 | 249.52 |
| Nov 26, 2024 | 252.85 | 4.04 | 1.62% | 248.81 | 253.45 | 245.43 |
| Nov 25, 2024 | 249.77 | 3.07 | 1.24% | 246.70 | 254.95 | 246.70 |
| Nov 22, 2024 | 244.66 | -0.69 | -0.28% | 245.35 | 247.91 | 241.29 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Alnylam Company profile
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
675 W Kendall St
CAMBRIDGE
MASSACHUSETTS 02142-1168
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com